相似文献
1
Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy.转甲状腺素蛋白淀粉样变心肌病的诊断与治疗进展
ESC Heart Fail. 2025 Jun;12(3):1529-1531. doi: 10.1002/ehf2.15166. Epub 2024 Nov 26.
2
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.肥厚型心肌病中甲状腺转运蛋白淀粉样变心肌病的患病率及特征
ESC Heart Fail. 2024 Dec;11(6):4314-4324. doi: 10.1002/ehf2.14971. Epub 2024 Aug 29.
3
Inotersen therapy of transthyretin amyloid cardiomyopathy.转甲状腺素蛋白淀粉样心肌病的伊诺特生治疗。
Amyloid. 2020 Mar;27(1):52-58. doi: 10.1080/13506129.2019.1685487. Epub 2019 Nov 12.
4
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy.他法米地对转甲状腺素蛋白淀粉样心肌病非试验患者血清转甲状腺素蛋白水平的影响
JACC CardioOncol. 2021 Oct 19;3(4):580-586. doi: 10.1016/j.jaccao.2021.08.007. eCollection 2021 Oct.
5
Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.转甲状腺素蛋白淀粉样心肌病——当前和未来的治疗方法。
Ann Pharmacother. 2021 Dec;55(12):1502-1514. doi: 10.1177/10600280211000351. Epub 2021 Mar 9.
6
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.用塔法米迪治疗转甲状腺素蛋白淀粉样心肌病患者的长期生存。
Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20.
7
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
8
Purification and characterization of amyloid-related transthyretin associated with familial amyloidotic cardiomyopathy.与家族性淀粉样心肌病相关的淀粉样变相关转甲状腺素蛋白的纯化与鉴定
Eur J Biochem. 1995 Feb 1;227(3):772-9. doi: 10.1111/j.1432-1033.1995.tb20200.x.
9
Case Report: A rare transthyretin mutation p.D58Y in a Chinese case of transthyretin amyloid cardiomyopathy.病例报告：1例中国转甲状腺素蛋白淀粉样变心肌病患者中罕见的转甲状腺素蛋白p.D58Y突变
Front Cardiovasc Med. 2024 May 22;11:1374241. doi: 10.3389/fcvm.2024.1374241. eCollection 2024.
10
Coexisting transthyretin and atrial natriuretic peptide amyloid on left atrium in transthyretin amyloid cardiomyopathy.转甲状腺素蛋白淀粉样心肌病患者左心房中并存的转甲状腺素蛋白和心房利钠肽淀粉样变
J Cardiol Cases. 2024 Mar 4;29(6):261-264. doi: 10.1016/j.jccase.2024.02.008. eCollection 2024 Jun.
本文引用的文献
1
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.肥厚型心肌病中甲状腺转运蛋白淀粉样变心肌病的患病率及特征
ESC Heart Fail. 2024 Dec;11(6):4314-4324. doi: 10.1002/ehf2.14971. Epub 2024 Aug 29.
2
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness.原因不明的左心室壁增厚患者的转甲状腺素蛋白淀粉样心肌病。
Int J Cardiovasc Imaging. 2024 Aug;40(8):1693-1703. doi: 10.1007/s10554-024-03158-z. Epub 2024 Jun 10.
3
Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society.转甲状腺素蛋白淀粉样变心肌病的诊断与治疗：波兰心脏病学会立场声明
Kardiol Pol. 2023;81(11):1167-1185. doi: 10.33963/v.kp.97648. Epub 2023 Sep 28.
4
Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records.从电子健康记录中自动提取数据检测转甲状腺素蛋白淀粉样心肌病。
ESC Heart Fail. 2023 Dec;10(6):3483-3492. doi: 10.1002/ehf2.14517. Epub 2023 Sep 19.
5
Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy.野生型转甲状腺素淀粉样变心肌病中塔法米迪的临床特征、结局和治疗效果。
ESC Heart Fail. 2023 Aug;10(4):2319-2329. doi: 10.1002/ehf2.14380. Epub 2023 Apr 18.
6
Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure.患有心脏淀粉样变性的患者在急性心力衰竭后死亡和再次入院的风险更高。
ESC Heart Fail. 2023 Jun;10(3):2042-2050. doi: 10.1002/ehf2.14337. Epub 2023 Apr 13.
7
Health-related quality of life among transthyretin amyloid cardiomyopathy patients.转甲状腺素蛋白淀粉样变心肌病患者的健康相关生活质量。
ESC Heart Fail. 2023 Jun;10(3):1871-1882. doi: 10.1002/ehf2.14350. Epub 2023 Mar 22.
8
Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis.经导管三尖瓣修复术治疗心脏淀粉样变性患者的初步经验。
ESC Heart Fail. 2023 Apr;10(2):1003-1012. doi: 10.1002/ehf2.14262. Epub 2022 Dec 13.
9
SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.SGLT2 抑制剂治疗转甲状腺素淀粉样变性心肌病：达格列净的早期耐受性和临床反应。
ESC Heart Fail. 2023 Feb;10(1):397-404. doi: 10.1002/ehf2.14188. Epub 2022 Oct 19.
10
Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).在腕管综合征手术（CACTuS）患者中鉴定野生型转甲状腺素蛋白心脏淀粉样变性。
ESC Heart Fail. 2023 Feb;10(1):234-244. doi: 10.1002/ehf2.14173. Epub 2022 Oct 3.
Zotero 插件